Monday to Sunday, including holidays: 8h - 20h
Phone number: 282 420 020
Av. S. João de Deus - Parque de Saúde da Misericordia de Portimão,
8500-508 Portimão
Opening Hours
Consultations and Exams
Monday to Friday: 8 am to 8.30 pm
Saturdays: 8am to 6pm
Sundays and Bank Holidays: 9am to 6pm
Clinical analysis
Monday to Saturday: 8am to 11am
Sundays and Bank Holidays: Closed
Urgent Care
Monday to Friday: 9 am to 8 pm
Weekends and Bank Holidays: 9 am to 6 pm
Internment
Daily: 24 hours
Opening Hours
Monday to Friday: 7am - 10pm
Saturdays, Sundays and Bank Holidays: 8 am - 10 pm
Urgent Care
Daily: 8am - 9pm
Clinical Analysis
Monday to Friday: 7am - 8pm
SaturdaySunday and Bank Holidays: 8am - 8pm
Av. General Humberto Delgado, Lote 7 7520-103 Sines
request appointment / exam
search
contacts
waiting times
Hospital Particular Alvor
00h58mUrgent Care
Hospital Particular Gambelas
00h04mUrgent Care
Over 1H30Paediatrics
Madeira Medical Center
01h25mUrgent Care
waiting times
Hospital Particular Alvor
00h58mUrgent Care
Hospital Particular Gambelas
00h04mUrgent Care
Over 1H30Paediatrics
Madeira Medical Center
01h25mUrgent Care
To make an appointment or book an examination, complete the form below with your personal details. We will subsequently send you an e-mail with confirmation/instructions.
Please note that information conserving Insurance agreements is merely informative. Therefore, please confirm that your particular Insurance Policy is contracted with us by completing the section “Observations” with your Insurance details.
Alternatively contact us on tel: 282 420 400 ( Algarve ) 269 630 370 ( Alentejo ) 291 00 33 00 (Madeira Island) or by email: callcenter@grupohpa.com ( Algarve) marcacoesalentejo@grupohpa.com ( Alentejo ) callcentermadeira@grupohpa.com (Madeira Island) .
All information can also be obtained at the Reception counter of any one of our Hospitals or Clinics.
Your request has been sent to the HPA Group successfully.
We will send send the availability of your appointment as soon as possible.
Thanks
Oncologist
An innovative oncology conquest
HPA Magazine 10
This new indication, approved by the FDA in December 2017, is a great advance in the treatment of this aggressive pathology, which has a high probability rate of recurrence following surgery.
Until now, in Europe, there has not been a standard adjuvant therapy recommended after melanoma surgery, because the treatment approved in the USA in 2015 - Ipilimumab (Yervoy®) – caused significant adverse effects in high-risk patients. The CheckMate-238 study compared Nivolumab vs. Ipilimumab and showed quite a significant reduction in recurrence of the disease and risk of death in stage 3 operations (melanoma with node involvement).
After this approval, additional evidence recently came from the KEYNOTE-054 study, which showed a benefit similar to Pembrolizumab (Keytruda®), another immunotherapy drug, in patients with similar characteristics. Therefore, we are witnessing an evolution that exceeds the indications and approvals for immunotherapy in advanced cancer (metastatic/stage 4) – melanoma, lung cancer, kidney cancer, Hodgkin’s lymphoma, cancer of the head and neck – for other pathologies and for earlier stages, which means that we can reduce the risk of this lethal disease recurring after curative surgery, without significant toxicity.
This fact can be explained by the mechanism of action of these drugs. Rather than having a direct cytotoxic effect on the cancerous cells (and also on the healthy cells) as happens with chemotherapy, immunotherapy (also an endovenous drug) acts by unblocking the inhibition of our immune system caused by the cancer and stimulates its cytotoxic action. Thus, in administering a 1-hour simple endovenous treatment, it can be given with a very manageable toxicity profile. At the moment, there are hundreds of clinical trials being carried out to explore the potential of this treatment in earlier stages in the most varied pathologies, isolated or in combination with standard treatments, with extremely promising results.
The HPA is proud to have its Oncology Unit involved in this process, especially the possibility to offer our patients the most advanced oncology treatments available.